Safety and tolerability of high-dose formoterol (via Aerolizer®) and salbutamol in patients with chronic obstructive pulmonary disease

Respiratory Medicine

Volumn 100, Issue 4, 2006, Pages 666-672

  Rosenkranz, Bernd ^a   Rouzier, Regine ^b   Kruse, Matthias ^a   Dobson, Clair ^c   Ayre, Gareth ^c   Horowitz, Ann ^d   Fitoussi, Serge ^e  

^a PAREXEL INTERNATIONAL   (United States)

^b Centre CAP   (France)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

^e LARIME   (France)

Author keywords

Aerolizer; COPD; High dose formoterol; Salbutamol; Tolerability

Indexed keywords

FORMOTEROL FUMARATE; LACTITOL; METOCLOPRAMIDE; PARACETAMOL; SALBUTAMOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; LUNG FUNCTION; MALE; METERED DOSE INHALER; MUSCLE STIFFNESS; NAUSEA; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREMOR; VIRAL GASTROENTERITIS;

ADMINISTRATION, INHALATION; ALBUTEROL; AREA UNDER CURVE; BLOOD GLUCOSE; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HEART RATE; HUMANS; MALE; MIDDLE AGED; POTASSIUM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33344467389     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2005.07.017     Document Type: Article

References (21)

1. Global initiative for chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. National Institutes of Health. National Heart, Lung, and Blood Institute. Publication No. 2701, updated March 2003.
2. R. Dahl L.A. Greefhorst D. Nowak et. al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease Am J Respir Crit Care Med 164 2001 778-784
3. R. Aalbers J. Ayres V. Backer et. al. Formoterol in patients with chronic obstructive pulmonary disease: A randomized, controlled, 3-month trial Eur Respir J 19 2002 936-943
4. A. Rossi P. Kristufek B.E. Levine et. al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD Chest 121 2002 1058-1069
5. D. Benhamou A. Cuvelier J-.F. Muir et. al. Rapid onset of bronchodilation in COPD: A placebo-controlled study comparing formoterol (Foradil Aerolizer®) with salbutamol (Ventodisk™) Respir Med 95 2001 817-821
6. M. Cazzola S. Centanni C. Regorda et. al. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD Pulm Pharmacol Ther 14 2001 41-45
7. American Thoracic Society Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 152 1995 S77-S120
8. J.B. Lecaillon G. Kaiser M. Palmisano J. Morgan G. Della Cioppa Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer™ Eur J Clin Pharmacol 55 1999 131-138
9. F.P.V. Maesen R. Costongs J.J. Smeets P.J. Brombacher P.G. Zweers The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations Chest 99 1991 1367-1373
10. A. Ullman C-.G. Löfdahl B. Melander N. Svedmyr Formoterol inhaled as dry powder or via pressurized metered-dose inhaler in a cumulative dose-response study Allergy 51 1996 745-748
11. C. Burgess M. Ayson S. Rajasingham J. Crane G. Della Cioppa M.D. Till The extrapulmonary effects of increasing doses of formoterol in patients with asthma Eur J Clin Pharmacol 54 1998 141-147
12. K.J. Tötterman L. Huhti E. Sutinen et. al. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients Eur Respir J 12 1998 573-579
13. M. Cazzola M. D'Amato C. Califano et. al. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease Clin Ther 24 2002 595-604
14. M. Cazzola P. Santus M.G. Matera et. al. A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD Respir Med 97 2003 458-462
15. J. Lötvall A. Mellen P. Arvidsson P. Radielovic J. Kottakis P. Pfister Similar bronchodilation with formoterol delivered by Aerolizer or Turbuhaler Can Respir J 6 1999 412-416
16. E. Wooltorton Salmeterol (Serevent) asthma trial halted early CMAJ 168 6 2003 738
17. M. Mann B. Chowdhury E. Sullivan R. Nicklas R. Anthracite R.J. Meyer Serious asthma exacerbations in asthmatics treated with high-dose formoterol Chest 124 2003 70-74
18. E. Israel J.M. Drazen S.B. Liggett et. al. Effect of the polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma Int Arch Allergy Immunol 124 2001 183-186
19. E. Israel V.M. Chinchilli J.G. Ford et. al. Use of regularly scheduled albuterol treatment in asthma: Genotype-stratified, randomised, placebo-controlled cross-over trial Lancet 364 2004 1505-1512
20. 2 adrenoceptor polymorphism Thorax 55 2000 762-767
21. L.I. Ho H.J. Harn C.J. Chen N.M. Tsai Polymorphism of the beta(2) adrenoceptor in COPD in Chinese subjects Chest 120 2001 1493-1499